Reactions 1680, p252 - 2 Dec 2017 Cutaneous and hepatic toxicities: 2 case reports In a cohort study, wherein patients were enrolled in a prospective as well as retrospective manner, two patients [ages and sexes not stated] were described, who developed hepatic and cutaneous toxicities during treatment with nilotinib. The patients, who had a history of chronic myeloid leukaemia, were started on nilotinib at an initial daily dose 600mg [routes not stated]. Subsequently, one of the two patients developed grade 4 hepatic toxicity, and other patient developed grade 4 cutaneous toxicity [durations of treatments to reactions onsets and outcomes not stated]. Author comment: "[I]n 2 cases toxicity was of grade 4 (one patient with hepatic toxicity, another one with cutaneous toxicity)." Galimberti S, et al. The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget 8: 88021-88033, No. 50, 30 Sep 2017. Available from: URL: http://doi.org/10.18632/ oncotarget.21406 - Italy 803285089 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera